Johnson & Johnson Reports Second-Quarter Earnings Alongside Biotech Study Results

Johnson & Johnson reported second-quarter earnings on July 15, 2026. In the OptiTROP-Lung05 study conducted in China, sac-TMT plus Keytruda delayed tumor progression compared to chemotherapy plus Keytruda in patients with first-line, PDL1-negative, non-squamous lung cancer, @statnews reported. A preliminary survival benefit favoring the sac-TMT arm was also reported.

This is the second China-run Phase 3 study of sac-TMT to show superiority over standard treatments in patients with lung cancer. Veradermics said its oral, extended-release formulation of minoxidil induced hair growth in women with mild-to-moderate pattern hair loss, achieving the goal of a single-arm midstage study.

The company is enrolling female participants in a Phase 2/3 study with results expected next year.

After the FDA’s former biologics chief, Vinay Prasad, pushed out several subordinates, overruled career scientists, and earned the ire of the rare disease community, his acting replacement is now tasked with calming the waters, @statnews reported.